The strong market-implied odds against a new pandemic in 2026 stem primarily from the absence of any novel pathogen demonstrating sustained human-to-human transmission or rapid global spread as of mid-year. Current CDC and WHO surveillance data show ongoing SARS-CoV-2 variants such as BA.3.2 circulating at low prevalence alongside seasonal influenza and RSV, without immune-escape properties driving severe case surges or hospitalization spikes beyond typical winter patterns. Isolated clusters, including a recent hantavirus incident on a cruise ship, remain contained due to limited transmissibility and no evidence of efficient airborne spread. Established genomic monitoring, population-level immunity from prior exposures, and routine public health protocols continue to suppress escalation, aligning with the historical rarity of pandemics outside major zoonotic spillover events.